Nicotinamide riboside - ChromaDex

Drug Profile

Nicotinamide riboside - ChromaDex

Alternative Names: NIAGEN

Latest Information Update: 01 Mar 2017

Price : $50

At a glance

  • Originator Cornell University; Dartmouth College; Washington University
  • Developer ChromaDex; National Institutes of Health (USA); University of Iowa
  • Class Amides; Nicotinic-acids; Pyridines; Small molecules; Vitamins
  • Mechanism of Action Nicotinamide adenine dinucleotide modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cockayne syndrome; Pain

Most Recent Events

  • 22 Feb 2017 Preclinical trials in Pain in USA (unspecified route)
  • 22 Feb 2017 Chromadex intends to file an Investigational New Drug (IND) application with the US FDA
  • 22 Feb 2017 Chromadex plans a phase I/II trial in Cockayne syndrome
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top